Published in J Clin Invest on December 01, 1994
MMP Polymorphisms and Acute Coronary Syndromes | NCT00484406
Macrophages in the pathogenesis of atherosclerosis. Cell (2011) 7.78
Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 4.52
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest (1996) 3.64
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007) 3.19
Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest (1998) 3.17
Obesity and free fatty acids. Endocrinol Metab Clin North Am (2008) 2.64
Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol (2001) 2.63
Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. Circ Cardiovasc Genet (2008) 2.50
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest (2005) 2.44
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res (1998) 2.39
The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol (1997) 2.29
Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A (2005) 2.19
Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest (1999) 2.16
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest (1998) 2.02
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 2.00
Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A (1995) 2.00
Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A (1996) 1.92
Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology (2009) 1.89
Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology (2006) 1.80
A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res (2009) 1.72
The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol (2000) 1.70
Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin, and talin. J Cell Biol (1999) 1.70
Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol (1996) 1.66
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol (2009) 1.65
Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest (1999) 1.64
"Gum bug, leave my heart alone!"--epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. J Dent Res (2010) 1.61
Emerging markers of atherosclerosis before and after bariatric surgery. Obes Surg (2015) 1.55
Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res (2009) 1.52
The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med (2008) 1.51
Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol (2009) 1.47
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest (1997) 1.45
T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol (2002) 1.45
MMP2 genetic variation is associated with measures of fibrous cap thickness: The Atherosclerosis Risk in Communities Carotid MRI Study. Atherosclerosis (2009) 1.45
Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol (1999) 1.42
Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J (2010) 1.41
Innate and adaptive immunity in atherosclerosis. Semin Immunopathol (2009) 1.40
Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest (2001) 1.40
IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest (2001) 1.39
Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol (2004) 1.39
Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol (1996) 1.38
Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol (2000) 1.38
Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab (2011) 1.37
Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res (2014) 1.36
MMP induction and inhibition in myocardial infarction. Heart Fail Rev (2004) 1.35
Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci U S A (2000) 1.34
Zymography methods for visualizing hydrolytic enzymes. Nat Methods (2013) 1.31
Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. Am J Pathol (1998) 1.27
Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol (2006) 1.24
Vascular endothelial growth factor and substrate mechanics regulate in vitro tubulogenesis of endothelial progenitor cells. J Cell Mol Med (2010) 1.24
ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest (2001) 1.24
The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol (2012) 1.22
Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target (2007) 1.21
Coronary artery remodelling is related to plaque composition. Heart (2005) 1.18
The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet (2006) 1.18
Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1. BMC Cell Biol (2005) 1.17
Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm (2012) 1.16
Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med (1999) 1.16
Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol (2008) 1.15
Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol (2008) 1.14
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol (2014) 1.14
Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats. Am J Pathol (2000) 1.13
Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol (1996) 1.13
Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol (1998) 1.13
BHUx: A Patent Polyherbal Formulation to Prevent Atherosclerosis. Evid Based Complement Alternat Med (2005) 1.13
Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart (2003) 1.13
Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A (1996) 1.12
PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patterns. Am J Physiol Heart Circ Physiol (2008) 1.12
Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits afer heterotopic cardiac transplantation. J Clin Invest (1996) 1.11
Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J (1996) 1.10
Imaging atherosclerosis and vulnerable plaque. J Nucl Med (2010) 1.10
Matrilysin-dependent elastolysis by human macrophages. J Exp Med (2003) 1.08
Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis (2008) 1.08
Collagenolytic and gelatinolytic matrix metalloproteinases and their inhibitors in basal cell carcinoma of skin: comparison with normal skin. Br J Cancer (2000) 1.07
A robust rabbit model of human atherosclerosis and atherothrombosis. J Lipid Res (2009) 1.06
Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One (2008) 1.06
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels (2007) 1.05
Association between arsenic exposure from drinking water and plasma levels of cardiovascular markers. Am J Epidemiol (2012) 1.05
Oxidized-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine induces vascular endothelial superoxide production: implication of NADPH oxidase. Free Radic Biol Med (2005) 1.05
Matrix metalloproteases and PAR1 activation. Blood (2012) 1.05
Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis (2009) 1.04
Matrix metalloproteinase activation predicts amelioration of remodeling after dietary modification in injured arteries. Arterioscler Thromb Vasc Biol (2010) 1.04
Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS (2012) 1.03
T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol (1999) 1.03
Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol (2011) 1.03
Matrix metalloproteinases in cardiovascular disease. Can J Cardiol (2006) 1.03
Monocytic cell type-specific transcriptional induction of collagenase. J Clin Invest (1996) 1.02
Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages. Toxicol Appl Pharmacol (2009) 1.02
Enhanced tyrosine nitration of prostacyclin synthase is associated with increased inflammation in atherosclerotic carotid arteries from type 2 diabetic patients. Am J Pathol (2010) 1.01
Cellular and molecular responses of the basilar terminus to hemodynamics during intracranial aneurysm initiation in a rabbit model. J Vasc Res (2011) 1.01
T-cell activation leads to reduced collagen maturation in atherosclerotic plaques of Apoe(-/-) mice. Am J Pathol (2009) 1.01
Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. Inflammation (1998) 1.01
Symptomatic and asymptomatic carotid artery plaque. Expert Rev Cardiovasc Ther (2011) 1.01
Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on Sirtuins. Int J Mol Sci (2013) 1.00
Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology (2007) 1.00
Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol (2002) 0.99
Non-destructive label-free monitoring of collagen gel remodeling using optical coherence tomography. Biomaterials (2010) 0.99
Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med (1987) 9.79
Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 8.29
Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A (1962) 5.94
Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet (1989) 4.96
The matrix-degrading metalloproteinases. Bioessays (1992) 4.84
Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol (1989) 3.82
Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J (1993) 3.54
Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J Biol Chem (1985) 3.51
Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation (1993) 3.29
Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem (1986) 3.24
Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem (1989) 2.87
Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A (1991) 2.53
Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res (1994) 2.46
Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res (1990) 2.40
Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol (1989) 2.39
Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem (1992) 2.34
Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J (1993) 2.28
Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem (1986) 2.26
Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A (1989) 2.26
Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol (1990) 2.22
Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest (1986) 2.21
Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci U S A (1989) 2.12
Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum (1992) 1.98
Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest (1986) 1.89
Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma (1993) 1.27
Coronary arterial remodeling studied by high-frequency epicardial echocardiography: an early compensatory mechanism in patients with obstructive coronary atherosclerosis. J Am Coll Cardiol (1991) 1.27
Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis (1991) 1.13
Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin. FEBS Lett (1988) 0.98
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell (1989) 6.26
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest (1995) 5.09
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation (2001) 3.47
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 3.31
Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest (1998) 3.17
Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol (1998) 3.04
An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb (1993) 2.77
The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci (2001) 2.75
Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation (1999) 2.73
Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol (1996) 2.68
Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol (2001) 2.63
Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation (1998) 2.63
Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A (1997) 2.56
Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol (1995) 2.54
Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation (2001) 2.53
Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol (2000) 2.50
Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res (1994) 2.46
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res (1998) 2.39
Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol (1989) 2.39
Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation (1999) 2.33
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest (1986) 2.21
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest (1999) 2.16
Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest (1999) 2.13
Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation (1997) 2.12
Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem (1995) 2.11
Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation (1998) 2.11
Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum (1993) 2.10
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 2.09
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol (1999) 2.07
The unstable atheroma. Arterioscler Thromb Vasc Biol (1997) 2.05
Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb (1991) 2.04
Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol (1983) 2.03
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (1999) 2.02
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 2.00
Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A (1995) 2.00
Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum (1992) 1.98
Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation (1999) 1.97
CD40 signaling and plaque instability. Circ Res (2001) 1.97
Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med (2001) 1.96
Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem (1992) 1.96
Leupeptin, a protease inhibitor, decreases protein degradation in normal and diseased muscles. Science (1978) 1.93
Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (1999) 1.86
Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest (1972) 1.86
Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol (1991) 1.82
Fatty acid modulation of endothelial activation. Am J Clin Nutr (2000) 1.81
Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol (1987) 1.79
Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem (1991) 1.79
Inflammation and thrombosis: the clot thickens. Circulation (2001) 1.79
Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest (1997) 1.77
Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest (1998) 1.76
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res (2001) 1.76
Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation (1999) 1.74
Injurious mechanical compression of bovine articular cartilage induces chondrocyte apoptosis. Arch Biochem Biophys (2000) 1.73
Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol (1996) 1.71
Novel inflammatory markers of coronary risk: theory versus practice. Circulation (1999) 1.65
Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk (2001) 1.65
Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol (1997) 1.65
Inducible expression of class II major histocompatibility complex antigens and the immunogenicity of vascular endothelium. Transplantation (1986) 1.64
Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A (2000) 1.63
Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med (1987) 1.61
The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res (2000) 1.60
Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol (1993) 1.58
Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. Arterioscler Thromb Vasc Biol (1999) 1.57
Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb (1991) 1.57
HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol (2000) 1.56
Implantation of vascular grafts lined with genetically modified endothelial cells. Science (1989) 1.54
Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun (1990) 1.54
Mechanical strain tightly controls fibroblast growth factor-2 release from cultured human vascular smooth muscle cells. Circ Res (1997) 1.54
Soluble CD40L and cardiovascular risk in women. Circulation (2001) 1.52
Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum (1995) 1.52